← Leaderboards
Charles A Thornton
Virginia Commonwealth University
$25,625,192
Attributed
$28,283,587
Total exposure
33
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$34,780,375 · 34
FDA$3,271,152 · 1
By mechanism
P50$10,351,422 · 4
R01$9,430,906 · 3
U54$7,162,335 · 4
U01$3,976,672 · 1
R37$2,453,064 · 1
R21$2,445,489 · 7
Top collaborators
- Nicholas Elwood Johnson6 shared
- Peter B. Dervan2 shared
- Joel M. Gottesfeld2 shared
- Johanna Hamel2 shared
Others in their field
Top investigators on “Myotonic Dystrophy”
- Laura Pw Ranum · University Of Minnesota Twin Cities$17,009,224
- Thomas Alexander Cooper · Baylor College Of Medicine$16,038,073
- Maurice S Swanson · University Of California, San Diego$15,936,599
- Richard T Moxley · University Of Rochester$12,413,577
- Lubov T Timchenko · Cincinnati Childrens Hosp Med Ctr$11,748,709
- Mani S Mahadevan · University Of Wisconsin Madison$11,184,338
Research focus
Myotonic DystrophyMuscular DystrophiesMouse ModelClinical TrialsMuscleRna SplicingSymptomsProteinsMyotoniaToxic EffectDefectClinical ResearchUntranslated RegionsGenesNuclearCell NucleusAlternative SplicingDesignTransgenic MiceMessenger RnaMutantAntisense OligonucleotidesAlleles3&Apos
Grant awards (119)
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type-1 (Renewal)$398,302
R01 · FY2025 · FD
Pharmacodynamic Biomarker of Myotonic Dystrophy$401,600
R61 · FY2024 · NS · contact PI
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type-1 (Renewal)$399,847
R01 · FY2024 · FD
Pharmacodynamic Biomarker of Myotonic Dystrophy$421,172
R61 · FY2023 · NS · contact PI
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center$1,377,719
P50 · FY2022 · NS · contact PI
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type-1 (Renewal)$386,995
R01 · FY2022 · FD
Disease progression and biomarkers in patients with myotonic dystrophy type 1 and 2$338,337
P50 · FY2022 · NS · contact PI
Preclinical models and therapies for myotonic dystrophy type 2$229,352
P50 · FY2022 · NS · contact PI
Administrative Core$93,828
P50 · FY2022 · NS · contact PI
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center$55,605
P50 · FY2022 · NS · contact PI
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center$1,368,669
P50 · FY2021 · NS · contact PI
Therapeutic Modulation of Myotonic Muscular Dystrophy$370,563
R37 · FY2021 · NS · contact PI
Disease progression and biomarkers in patients with myotonic dystrophy type 1 and 2$324,275
P50 · FY2021 · NS · contact PI
Preclinical models and therapies for myotonic dystrophy type 2$230,845
P50 · FY2021 · NS · contact PI
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type-1$98,005
R01 · FY2021 · FD
Administrative Core$93,878
P50 · FY2021 · NS · contact PI
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center$55,605
P50 · FY2021 · NS · contact PI
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center$1,369,485
P50 · FY2020 · NS · contact PI
Therapeutic Modulation of Myotonic Muscular Dystrophy$370,563
R37 · FY2020 · NS · contact PI
Disease progression and biomarkers in patients with myotonic dystrophy type 1 and 2$309,095
P50 · FY2020 · NS · contact PI
Preclinical models and therapies for myotonic dystrophy type 2$231,199
P50 · FY2020 · NS · contact PI
Administrative Core$93,108
P50 · FY2020 · NS · contact PI
Mechanism of action of small molecule therapeutics for myotonic dystrophy type 1$65,206
P50 · FY2020 · NS · contact PI
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center$1,368,622
P50 · FY2019 · NS · contact PI
Therapeutic Modulation of Myotonic Muscular Dystrophy$370,563
R37 · FY2019 · NS · contact PI
Disease progression and biomarkers in patients with myotonic dystrophy type 1 and 2$308,722
P50 · FY2019 · NS · contact PI
Preclinical models and therapies for myotonic dystrophy type 2$234,922
P50 · FY2019 · NS · contact PI
Administrative Core$100,223
P50 · FY2019 · NS · contact PI
12th International Myotonic Dystrophy Consortium Meeting (IDMC-12)$20,000
R13 · FY2019 · NS · contact PI
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center$1,425,349
P50 · FY2018 · NS · contact PI
Therapeutic Modulation of Myotonic Muscular Dystrophy$336,875
R37 · FY2018 · NS · contact PI
Disease progression and biomarkers in patients with myotonic dystrophy type 1 and 2$325,577
P50 · FY2018 · NS · contact PI
Preclinical models and therapies for myotonic dystrophy type 2$250,075
P50 · FY2018 · NS · contact PI
Administrative Core$101,726
P50 · FY2018 · NS · contact PI
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type-1$1,961,707
R01 · FY2017 · FD
Paul D. Wellstone Muscular Dystrophy Cooperative Research Center$1,316,135
U54 · FY2017 · NS · contact PI
Therapeutic Modulation of Myotonic Muscular Dystrophy$336,875
R37 · FY2017 · NS · contact PI
Training and Educational Core$138,884
U54 · FY2017 · NS · contact PI
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type-1$26,296
R01 · FY2017 · FD
11th International Myotonic Dystrophy Consortium Meeting$22,500
R13 · FY2017 · NS · contact PI
Paul D. Wellstone Muscular Dystrophy Cooperative Research Center$1,365,545
U54 · FY2016 · NS · contact PI
Therapeutic Modulation of Myotonic Muscular Dystrophy$335,963
R37 · FY2016 · NS · contact PI
Biomarkers of therapeutic response in myotonic dystrophy$191,875
R21 · FY2016 · NS · contact PI
Training and Educational Core$138,884
U54 · FY2016 · NS · contact PI
Transcription therapeutics for myotonic dystrophy type 1$436,200
R21 · FY2015 · NS
Therapeutic Modulation of Myotonic Muscular Dystrophy$331,662
R37 · FY2015 · NS · contact PI
Biomarkers of therapeutic response in myotonic dystrophy$230,250
R21 · FY2015 · NS · contact PI
Training and Educational Core$138,884
U54 · FY2015 · NS · contact PI
Antisense oligonucleotide treatment for myotonic dystrophy$772,323
U01 · FY2014 · NS · contact PI
Transcription therapeutics for myotonic dystrophy type 1$480,950
R21 · FY2014 · NS
Training and Educational Core$137,494
U54 · FY2014 · NS · contact PI
Antisense oligonucleotide treatment for myotonic dystrophy$1,728,823
U01 · FY2013 · NS · contact PI
Training and Educational Core$138,884
U54 · FY2013 · NS · contact PI
Antisense oligonucleotide treatment for myotonic dystrophy$920,983
U01 · FY2012 · NS · contact PI
Experimental Therapy of Myotonic Dystrophy$383,806
U54 · FY2012 · NS · contact PI
Integrative Pathophysiology of Myotonic Dystrophy$119,295
K24 · FY2012 · AR · contact PI
Antisense oligonucleotide treatment for myotonic dystrophy$554,543
U01 · FY2011 · NS · contact PI
Experimental Therapy of Myotonic Dystrophy$405,259
U54 · FY2011 · NS · contact PI
RNA-mediated mechanisms in the myotonic dystrophies$308,383
R01 · FY2011 · AR · contact PI
Integrative Pathophysiology of Myotonic Dystrophy$125,253
K24 · FY2011 · AR · contact PI
Experimental Therapy of Myotonic Dystrophy$405,624
U54 · FY2010 · NS · contact PI
RNA-mediated mechanisms in the myotonic dystrophies$321,233
R01 · FY2010 · AR · contact PI
Integrative Pathophysiology of Myotonic Dystrophy$125,253
K24 · FY2010 · AR · contact PI
Experimental Therapy of Myotonic Dystrophy$477,619
U54 · FY2009 · NS · contact PI
RNA-mediated mechanisms in the myotonic dystrophies$324,478
R01 · FY2009 · AR · contact PI
Pathogenesis of Myopathy in Models of Myotonic Dystrophy$318,908
R01 · FY2009 · AR · contact PI
Integrative Pathophysiology of Myotonic Dystrophy$125,253
K24 · FY2009 · AR · contact PI
Pathogenesis of Myopathy in Models of Myotonic Dystrophy$73,615
R01 · FY2009 · AR · contact PI
Inhibitors of MBNL1 - poly(CUG)binding$24,972
R03 · FY2009 · MH · contact PI
Experimental Therapy of Myotonic Dystrophy$655,953
U54 · FY2008 · NS · contact PI
RNA-mediated mechanisms in the myotonic dystrophies$324,478
R01 · FY2008 · AR · contact PI
Pathogenesis of Myopathy in Models of Myotonic Dystrophy$318,908
R01 · FY2008 · AR · contact PI
Therapeutic approach targeting RNA disease in myotonic dystrophy$199,365
R21 · FY2008 · NS · contact PI
Model of OPMD with constitutive PABPN1 expression$168,438
R21 · FY2008 · NS · contact PI
Integrative Pathophysiology of Myotonic Dystrophy$125,253
K24 · FY2008 · AR · contact PI
RNA-mediated mechanisms in the myotonic dystrophies$331,100
R01 · FY2007 · AR · contact PI
Pathogenesis of Myopathy in Models of Myotonic Dystrophy$325,416
R01 · FY2007 · AR · contact PI
CORE--RESEARCH RESOURCES$283,974
U54 · FY2007 · NS · contact PI
Therapeutic approach targeting RNA disease in myotonic dystrophy$165,036
R21 · FY2007 · NS · contact PI
Model of OPMD with constitutive PABPN1 expression$134,750
R21 · FY2007 · NS · contact PI
Pathogenesis of Myopathy in Models of Myotonic Dystrophy$335,135
R01 · FY2006 · AR · contact PI
CORE--RESEARCH RESOURCES$290,380
U54 · FY2006 · NS · contact PI
Integrative pathophysiology of myotonic dystrophy$105,620
K24 · FY2006 · AR · contact PI
RNA-mediated Mechanisms in the Myotonic Dystrophies$370,125
R01 · FY2005 · AR
Pathogenesis of Myopathy in Models of Myotonic Dystrophy$343,200
R01 · FY2005 · AR
CORE--RESEARCH RESOURCES$294,330
U54 · FY2005 · NS
Integrative pathophysiology of myotonic dystrophy$103,330
K24 · FY2005 · AR
FUNCTIONAL GENOMICS IN MUSCULAR DYSTROPHY$18,019
M01 · FY2005 · RR
CLINICAL TRIAL OF INSULIN-LIKE GROWTH FACTOR-1 IN AMYOTROPHIC LATERAL SCLEROSIS$7,685
M01 · FY2005 · RR
MODEL OF NEUROLOGIC IMPAIRMENT IN MYOTONIC DYSTROPHY$351,905
R01 · FY2004 · AR
RNA-mediated Mechanisms in the Myotonic Dystrophies$343,744
R01 · FY2004 · AR
CORE--RESEARCH RESOURCES$292,429
U54 · FY2004 · NS
Integrative pathophysiology of myotonic dystrophy$101,106
K24 · FY2004 · AR
Clinical Trial of Insulin-Like Growth Factor-1 in ALS$8,068
M01 · FY2004 · RR
Functional Genomics in Muscular Dystrophy$3,797
M01 · FY2004 · RR
MODEL OF NEUROLOGIC IMPAIRMENT IN MYOTONIC DYSTROPHY$351,905
R01 · FY2003 · AR
RNA-mediated Mechanisms in the Myotonic Dystrophies$343,744
R01 · FY2003 · AR
CORE--RESEARCH RESOURCES$298,251
U54 · FY2003 · NS
Integrative pathophysiology of myotonic dystrophy$98,947
K24 · FY2003 · AR
RNA-mediated Mechanisms in the Myotonic Dystrophies$369,667
R01 · FY2002 · AR
MODEL OF NEUROLOGIC IMPAIRMENT IN MYOTONIC DYSTROPHY$351,905
R01 · FY2002 · AR
Integrative pathophysiology of myotonic dystrophy$96,852
K24 · FY2002 · AR
Transgenic Model of Oculopharyngeal Dystrophy$79,750
R21 · FY2002 · AR
DEHYDROEPIANDROSTERONES IN MYOTONIC DYSTROPHY$0
M01 · FY2002 · RR
PATHOPHYSIOLOGY OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY$0
M01 · FY2002 · RR
OL TRIAL OF INTRACEREBROVENTRICULAR R METHUGDNF FOR TREATMENT OF PATI$0
M01 · FY2002 · RR
MODEL OF NEUROLOGIC IMPAIRMENT IN MYOTONIC DYSTROPHY$351,905
R01 · FY2001 · AR
Transgenic Model of Oculopharyngeal Dystrophy$79,750
R21 · FY2001 · AR
CONDITIONAL MODEL OF MYOTONIC DYSTROPHY$79,750
R21 · FY2001 · AR
COMPARISON OF GAMMAR IVIG/PLACEBO IN DEMYELINATING POLYNEUROPATHY$19,613
M01 · FY2001 · RR
INTRAVENOUS IMMUNOGLOBULIN IN GENERALIZED MYASTHENIA GRAVIS$19,613
M01 · FY2001 · RR
RELIABILITY TESTING OF QUANTITATIVE MUSCLE ASSESSMENT (QMA)$19,613
M01 · FY2001 · RR
ICV ADMINISTRATION OF GDNF IN ALS PATIENTS$19,613
M01 · FY2001 · RR
PLAN FOR A TRIAL OF DHEAS IN MYOTONIC DYSTROPHY$119,625
R21 · FY2000 · AR
QUANTITATIVE ASSESSMENT OF MUSCLE STRENGTH AND FATIGUE$99,212
R41 · FY2000 · AR
CONDITIONAL MODEL OF MYOTONIC DYSTROPHY$79,750
R21 · FY2000 · AR
PATHOPHYSIOLOGY OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY$0
M01 · FY2000 · RR
DEHYDROEPIANDROSTERONES IN MYOTONIC DYSTROPHY$0
M01 · FY2000 · RR
OL TRIAL OF INTRACEREBROVENTRICULAR R METHUGDNF FOR TREATMENT OF PATI$0
M01 · FY2000 · RR